A Phase II Study of Docetaxel, Cisplatin and 5- Fluorouracil (TPF) In Patients with Locally Advanced Head and Neck Carcinomas

摘要: Background: The combination of cisplatin and 5-fluorouracil (PF) is currently considered a standard effective regimen for the treatment advanced head neck carcinomas. aim this study was to evaluate efficacy safety docetaxel, (TPF) in patients with unresectable Methods: Forty-six previously untreated non-metastatic stage IV carcinomas were enrolled. All received three cycles induction chemotherapy docetaxel (75 mg/m 2 ), (40 ) (days 1-2), 5-FU (500 , days 1-3), repeated every 21 days. Following chemotherapy, all underwent concurrent chemoradiotherapy using weekly (30 median total dose 70 Gy delivered. Clinical response rate toxicity primary secondary end-points study. Results: There 31 men 15 women. had (T2-3N2-3 or T4N0-3) disease. Overall complete rates 74% 24% respectively. Advanced T4 classification associated poorer (p value=0.042). major (grade 3-4) treatment-related toxicities myelosuppression (78%), anorexia (13%), diarrhea (7%), emesis (11%) stomatitis/pharyngitis (24%). Conclusion: In comparison data historical published trials PF regimen, TPF more effective. However, appears be higher incidence toxicities. Therefore, our limited findings support as an alternative chemotherapeutic